JP5973118B2 - ピラゾロン化合物含有水溶液が充填されたプラスチック容器 - Google Patents
ピラゾロン化合物含有水溶液が充填されたプラスチック容器 Download PDFInfo
- Publication number
- JP5973118B2 JP5973118B2 JP2007544193A JP2007544193A JP5973118B2 JP 5973118 B2 JP5973118 B2 JP 5973118B2 JP 2007544193 A JP2007544193 A JP 2007544193A JP 2007544193 A JP2007544193 A JP 2007544193A JP 5973118 B2 JP5973118 B2 JP 5973118B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- pyrazolin
- methyl
- plastic container
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 pyrazolone compound Chemical class 0.000 title claims description 56
- 229920003023 plastic Polymers 0.000 title claims description 53
- 239000004033 plastic Substances 0.000 title claims description 53
- 239000007864 aqueous solution Substances 0.000 title claims description 25
- 239000004698 Polyethylene Substances 0.000 claims description 17
- 229920000573 polyethylene Polymers 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 14
- 238000001802 infusion Methods 0.000 claims description 12
- 238000003860 storage Methods 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- 229920000089 Cyclic olefin copolymer Polymers 0.000 claims description 7
- 238000002835 absorbance Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000003635 deoxygenating effect Effects 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 description 35
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 27
- 235000002639 sodium chloride Nutrition 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000004040 coloring Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229920000098 polyolefin Polymers 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 11
- 229920001577 copolymer Polymers 0.000 description 11
- 239000000654 additive Substances 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 10
- 238000004659 sterilization and disinfection Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000004743 Polypropylene Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 229950009041 edaravone Drugs 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000003002 pH adjusting agent Substances 0.000 description 9
- 229920001155 polypropylene Polymers 0.000 description 9
- 239000012453 solvate Substances 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 229920001971 elastomer Polymers 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 5
- 239000005038 ethylene vinyl acetate Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 5
- 239000004800 polyvinyl chloride Substances 0.000 description 5
- 229920000915 polyvinyl chloride Polymers 0.000 description 5
- 239000005060 rubber Substances 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229940123973 Oxygen scavenger Drugs 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- OFVZVWFKZZQGBN-UHFFFAOYSA-N 2-(4-butoxyphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound C1=CC(OCCCC)=CC=C1N1C(=O)CC(C)=N1 OFVZVWFKZZQGBN-UHFFFAOYSA-N 0.000 description 2
- GVDAHXDXFJMVFS-UHFFFAOYSA-N 2-(4-butylphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound C1=CC(CCCC)=CC=C1N1C(=O)CC(C)=N1 GVDAHXDXFJMVFS-UHFFFAOYSA-N 0.000 description 2
- WHIXQFSPEDIMGL-UHFFFAOYSA-N 2-(4-chlorophenyl)-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=C(Cl)C=C1 WHIXQFSPEDIMGL-UHFFFAOYSA-N 0.000 description 2
- UAJMXYVLALDCCI-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=C(O)C=C1 UAJMXYVLALDCCI-UHFFFAOYSA-N 0.000 description 2
- FBFCBNWVKOBJLV-UHFFFAOYSA-N 2-(4-methoxyphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)CC(C)=N1 FBFCBNWVKOBJLV-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- YAVQZXBVUORYNQ-UHFFFAOYSA-N 5-methyl-2-(4-methylphenyl)-1h-pyrazol-3-one Chemical compound N1C(C)=CC(=O)N1C1=CC=C(C)C=C1 YAVQZXBVUORYNQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 229920006255 plastic film Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NDELSWXIAJLWOU-UHFFFAOYSA-N 2,5-dimethyl-4h-pyrazol-3-one Chemical compound CN1N=C(C)CC1=O NDELSWXIAJLWOU-UHFFFAOYSA-N 0.000 description 1
- MZKALFCNIJHTJG-UHFFFAOYSA-N 2,5-diphenyl-4h-pyrazol-3-one Chemical compound O=C1CC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MZKALFCNIJHTJG-UHFFFAOYSA-N 0.000 description 1
- CWESERWNUIUBJU-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1Cl CWESERWNUIUBJU-UHFFFAOYSA-N 0.000 description 1
- NKEKJMZYHSVIAZ-UHFFFAOYSA-N 2-(2-hydroxyethyl)-5-methyl-4h-pyrazol-3-one Chemical compound CC1=NN(CCO)C(=O)C1 NKEKJMZYHSVIAZ-UHFFFAOYSA-N 0.000 description 1
- RTNRIGKGQLASIJ-UHFFFAOYSA-N 2-(2-hydroxyphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1O RTNRIGKGQLASIJ-UHFFFAOYSA-N 0.000 description 1
- LZZDWKISOYRMAA-UHFFFAOYSA-N 2-(2-methoxyphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound COC1=CC=CC=C1N1C(=O)CC(C)=N1 LZZDWKISOYRMAA-UHFFFAOYSA-N 0.000 description 1
- NPLZMVKJNPOHRL-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=C(Cl)C(Cl)=C1 NPLZMVKJNPOHRL-UHFFFAOYSA-N 0.000 description 1
- RMOKNHGNDASXBP-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=C(O)C(O)=C1 RMOKNHGNDASXBP-UHFFFAOYSA-N 0.000 description 1
- LDSJFQFZGIHBAW-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound C1=C(OC)C(OC)=CC=C1N1C(=O)CC(C)=N1 LDSJFQFZGIHBAW-UHFFFAOYSA-N 0.000 description 1
- GJBBAPXESBCGRU-UHFFFAOYSA-N 2-(3,4-dimethylphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=C(C)C(C)=C1 GJBBAPXESBCGRU-UHFFFAOYSA-N 0.000 description 1
- UKTMRPNPEMPQMC-UHFFFAOYSA-N 2-(3-chloro-4-methylphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=C(C)C(Cl)=C1 UKTMRPNPEMPQMC-UHFFFAOYSA-N 0.000 description 1
- RIOMUJXIGYZENC-UHFFFAOYSA-N 2-(3-chlorophenyl)-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=CC(Cl)=C1 RIOMUJXIGYZENC-UHFFFAOYSA-N 0.000 description 1
- YIOLBBFTNHBTIE-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=CC(O)=C1 YIOLBBFTNHBTIE-UHFFFAOYSA-N 0.000 description 1
- UGUFALKCBVCZNF-UHFFFAOYSA-N 2-(3-methoxyphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound COC1=CC=CC(N2C(CC(C)=N2)=O)=C1 UGUFALKCBVCZNF-UHFFFAOYSA-N 0.000 description 1
- VNXUPEPDMYVBQY-UHFFFAOYSA-N 2-(4-aminophenyl)-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=C(N)C=C1 VNXUPEPDMYVBQY-UHFFFAOYSA-N 0.000 description 1
- DFQPWWDYYNSRQV-UHFFFAOYSA-N 2-(4-bromophenyl)-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=C(Br)C=C1 DFQPWWDYYNSRQV-UHFFFAOYSA-N 0.000 description 1
- YHMJWTXJAHETSE-UHFFFAOYSA-N 2-(4-chlorophenyl)-5-phenyl-4h-pyrazol-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)CC(C=2C=CC=CC=2)=N1 YHMJWTXJAHETSE-UHFFFAOYSA-N 0.000 description 1
- CELLPPBUIBRAQQ-UHFFFAOYSA-N 2-(4-ethoxyphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound C1=CC(OCC)=CC=C1N1C(=O)CC(C)=N1 CELLPPBUIBRAQQ-UHFFFAOYSA-N 0.000 description 1
- WVBMMAGKFYAKIT-UHFFFAOYSA-N 2-(4-ethylphenyl)-5-methyl-4h-pyrazol-3-one Chemical compound C1=CC(CC)=CC=C1N1C(=O)CC(C)=N1 WVBMMAGKFYAKIT-UHFFFAOYSA-N 0.000 description 1
- VJVFAPBCFDWAEX-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=C(F)C=C1 VJVFAPBCFDWAEX-UHFFFAOYSA-N 0.000 description 1
- POVAHURHEIOXAB-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-5-phenyl-4h-pyrazol-3-one Chemical compound C1=CC(O)=CC=C1N1C(=O)CC(C=2C=CC=CC=2)=N1 POVAHURHEIOXAB-UHFFFAOYSA-N 0.000 description 1
- KTRYFZMYJCEPBG-UHFFFAOYSA-N 2-(4-methoxyphenyl)-5-phenyl-4h-pyrazol-3-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)CC(C=2C=CC=CC=2)=N1 KTRYFZMYJCEPBG-UHFFFAOYSA-N 0.000 description 1
- BMEQSLZZTSYNTR-UHFFFAOYSA-N 2-(4-methylphenyl)-5-phenyl-4h-pyrazol-3-one Chemical compound C1=CC(C)=CC=C1N1C(=O)CC(C=2C=CC=CC=2)=N1 BMEQSLZZTSYNTR-UHFFFAOYSA-N 0.000 description 1
- YQRMIAZEABDTOX-UHFFFAOYSA-N 2-[4-(butylamino)phenyl]-5-methyl-4h-pyrazol-3-one Chemical compound C1=CC(NCCCC)=CC=C1N1C(=O)CC(C)=N1 YQRMIAZEABDTOX-UHFFFAOYSA-N 0.000 description 1
- JKEWJTOBDLUVMN-UHFFFAOYSA-N 2-[4-(dimethylamino)phenyl]-5-methyl-4h-pyrazol-3-one Chemical compound C1=CC(N(C)C)=CC=C1N1C(=O)CC(C)=N1 JKEWJTOBDLUVMN-UHFFFAOYSA-N 0.000 description 1
- ZSCDWPUAOYHVHO-UHFFFAOYSA-N 2-[4-(ethylamino)phenyl]-5-methyl-4h-pyrazol-3-one Chemical compound C1=CC(NCC)=CC=C1N1C(=O)CC(C)=N1 ZSCDWPUAOYHVHO-UHFFFAOYSA-N 0.000 description 1
- NYCKNDCJKMLXJE-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenyl]-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=C(CO)C=C1 NYCKNDCJKMLXJE-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- MEDQPHZEAUFCTK-UHFFFAOYSA-N 2-benzyl-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1CC1=CC=CC=C1 MEDQPHZEAUFCTK-UHFFFAOYSA-N 0.000 description 1
- URLKJZYEIINRBY-UHFFFAOYSA-N 2-butyl-5-methyl-4h-pyrazol-3-one Chemical compound CCCCN1N=C(C)CC1=O URLKJZYEIINRBY-UHFFFAOYSA-N 0.000 description 1
- CLCIJTSYLYHCAX-UHFFFAOYSA-N 2-cyclohexyl-5-methyl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1CCCCC1 CLCIJTSYLYHCAX-UHFFFAOYSA-N 0.000 description 1
- BDKWKEPROQIWCA-UHFFFAOYSA-N 2-ethyl-5-methyl-4h-pyrazol-3-one Chemical compound CCN1N=C(C)CC1=O BDKWKEPROQIWCA-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- NIXIJMXBXHWPEK-UHFFFAOYSA-N 2-methyl-5-phenyl-4h-pyrazol-3-one Chemical compound C1C(=O)N(C)N=C1C1=CC=CC=C1 NIXIJMXBXHWPEK-UHFFFAOYSA-N 0.000 description 1
- FTCOWMWIZNVSPP-UHFFFAOYSA-N 2-phenyl-4h-pyrazol-3-one Chemical compound O=C1CC=NN1C1=CC=CC=C1 FTCOWMWIZNVSPP-UHFFFAOYSA-N 0.000 description 1
- DXQSVRLYPGKQNS-UHFFFAOYSA-N 2-phenyl-5-propyl-4h-pyrazol-3-one Chemical compound O=C1CC(CCC)=NN1C1=CC=CC=C1 DXQSVRLYPGKQNS-UHFFFAOYSA-N 0.000 description 1
- NHLAPJMCARJFOG-UHFFFAOYSA-N 3-methyl-1,4-dihydropyrazol-5-one Chemical compound CC1=NNC(=O)C1 NHLAPJMCARJFOG-UHFFFAOYSA-N 0.000 description 1
- BQCMHLUBBYCYFL-UHFFFAOYSA-N 4,5-dimethyl-2-phenyl-4h-pyrazol-3-one Chemical compound O=C1C(C)C(C)=NN1C1=CC=CC=C1 BQCMHLUBBYCYFL-UHFFFAOYSA-N 0.000 description 1
- AVOONTISHAAFGN-UHFFFAOYSA-N 4-(2-hydroxyethyl)-5-methyl-2-phenyl-4h-pyrazol-3-one Chemical compound O=C1C(CCO)C(C)=NN1C1=CC=CC=C1 AVOONTISHAAFGN-UHFFFAOYSA-N 0.000 description 1
- CUGBBQWDGCXWNB-UHFFFAOYSA-N 4-(3-methyl-5-oxo-4h-pyrazol-1-yl)benzoic acid Chemical compound O=C1CC(C)=NN1C1=CC=C(C(O)=O)C=C1 CUGBBQWDGCXWNB-UHFFFAOYSA-N 0.000 description 1
- LDWDOWUYGPZPLX-UHFFFAOYSA-N 4-(3-methyl-5-oxo-4h-pyrazol-1-yl)benzonitrile Chemical compound O=C1CC(C)=NN1C1=CC=C(C#N)C=C1 LDWDOWUYGPZPLX-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ITUBXYGHGAJZAX-UHFFFAOYSA-N 5-ethyl-2-phenyl-4h-pyrazol-3-one Chemical compound O=C1CC(CC)=NN1C1=CC=CC=C1 ITUBXYGHGAJZAX-UHFFFAOYSA-N 0.000 description 1
- GENSTRUCMIZOCD-UHFFFAOYSA-N 5-methyl-2-(2-methylphenyl)-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1C GENSTRUCMIZOCD-UHFFFAOYSA-N 0.000 description 1
- GWHZXIMAQAFUCP-UHFFFAOYSA-N 5-methyl-2-(3-methylphenyl)-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=CC(C)=C1 GWHZXIMAQAFUCP-UHFFFAOYSA-N 0.000 description 1
- BGCHXYZBLCKRFJ-UHFFFAOYSA-N 5-methyl-2-(3-methylsulfanylphenyl)-4h-pyrazol-3-one Chemical compound CSC1=CC=CC(N2C(CC(C)=N2)=O)=C1 BGCHXYZBLCKRFJ-UHFFFAOYSA-N 0.000 description 1
- UKKHTJNGDHAKDN-UHFFFAOYSA-N 5-methyl-2-(4-methylsulfanylphenyl)-4h-pyrazol-3-one Chemical compound C1=CC(SC)=CC=C1N1C(=O)CC(C)=N1 UKKHTJNGDHAKDN-UHFFFAOYSA-N 0.000 description 1
- MYPAMGFTHVEING-UHFFFAOYSA-N 5-methyl-2-(4-nitrophenyl)-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=C([N+]([O-])=O)C=C1 MYPAMGFTHVEING-UHFFFAOYSA-N 0.000 description 1
- CMYZMINQZCXYEJ-UHFFFAOYSA-N 5-methyl-2-(4-propoxyphenyl)-4h-pyrazol-3-one Chemical compound C1=CC(OCCC)=CC=C1N1C(=O)CC(C)=N1 CMYZMINQZCXYEJ-UHFFFAOYSA-N 0.000 description 1
- XJBDDOACXUQATJ-UHFFFAOYSA-N 5-methyl-2-(4-propylphenyl)-4h-pyrazol-3-one Chemical compound C1=CC(CCC)=CC=C1N1C(=O)CC(C)=N1 XJBDDOACXUQATJ-UHFFFAOYSA-N 0.000 description 1
- FLRFRVFQDVMRPE-UHFFFAOYSA-N 5-methyl-2-[3-(trifluoromethyl)phenyl]-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=CC(C(F)(F)F)=C1 FLRFRVFQDVMRPE-UHFFFAOYSA-N 0.000 description 1
- ILBGNWVRGZBZFQ-UHFFFAOYSA-N 5-methyl-2-[4-(methylamino)phenyl]-4h-pyrazol-3-one Chemical compound C1=CC(NC)=CC=C1N1C(=O)CC(C)=N1 ILBGNWVRGZBZFQ-UHFFFAOYSA-N 0.000 description 1
- XOAVQFOOGPXSPI-UHFFFAOYSA-N 5-methyl-2-[4-(trifluoromethyl)phenyl]-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=C(C(F)(F)F)C=C1 XOAVQFOOGPXSPI-UHFFFAOYSA-N 0.000 description 1
- BTUGYRPOCOUJAE-UHFFFAOYSA-N 5-methyl-2-naphthalen-1-yl-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1C1=CC=CC2=CC=CC=C12 BTUGYRPOCOUJAE-UHFFFAOYSA-N 0.000 description 1
- BGVXJZCAHWGDCB-UHFFFAOYSA-N 5-methyl-2-phenyl-4-phenylsulfanyl-4h-pyrazol-3-one Chemical compound CC1=NN(C=2C=CC=CC=2)C(=O)C1SC1=CC=CC=C1 BGVXJZCAHWGDCB-UHFFFAOYSA-N 0.000 description 1
- YOQLDYYUCQUBHZ-UHFFFAOYSA-N 5-methyl-4-(2-methylpropyl)-2-phenyl-4h-pyrazol-3-one Chemical compound O=C1C(CC(C)C)C(C)=NN1C1=CC=CC=C1 YOQLDYYUCQUBHZ-UHFFFAOYSA-N 0.000 description 1
- VCFAGOKQNQOBOF-UHFFFAOYSA-N 5-methyl-4-phenoxy-2-phenyl-4h-pyrazol-3-one Chemical compound CC1=NN(C=2C=CC=CC=2)C(=O)C1OC1=CC=CC=C1 VCFAGOKQNQOBOF-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002433 Vinyl chloride-vinyl acetate copolymer Polymers 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- BXOUVIIITJXIKB-UHFFFAOYSA-N ethene;styrene Chemical group C=C.C=CC1=CC=CC=C1 BXOUVIIITJXIKB-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- YSNRXCNLMQFZGG-UHFFFAOYSA-N ethyl 2-(5-oxo-1-phenyl-4h-pyrazol-3-yl)acetate Chemical compound O=C1CC(CC(=O)OCC)=NN1C1=CC=CC=C1 YSNRXCNLMQFZGG-UHFFFAOYSA-N 0.000 description 1
- MYRBZWVVQLOLBF-UHFFFAOYSA-N ethyl 4-(3-methyl-5-oxo-4h-pyrazol-1-yl)benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1N1C(=O)CC(C)=N1 MYRBZWVVQLOLBF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229920000092 linear low density polyethylene Polymers 0.000 description 1
- 239000004707 linear low-density polyethylene Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- ACJQGMMFMUDLQX-UHFFFAOYSA-N n-[2-(3-methyl-5-oxo-4h-pyrazol-1-yl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1N1C(=O)CC(C)=N1 ACJQGMMFMUDLQX-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229920006132 styrene block copolymer Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N vinyl-ethylene Natural products C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Description
で表されるピラゾロン誘導体若しくはその生理的に許容される塩、又はそれらの水和物若しくは溶媒和物を有効成分として含有する水溶液を充填しているプラスチック容器が提供される。
好ましくは、60℃で4週間保存前後におけるプラスチックの黄色方向の色度b*(L*a*b*表色系)が実質的に変化しない。
好ましくは、プラスチック容器の黄色方向の色度b*(L*a*b*表色系)の変化Δb*は2以下である。
好ましくは、60℃で4週間の保存中において薬液は実質的に着色しない。
好ましくは、60℃で4週間の保存中において、薬液の波長400nmでの吸光度は0.010以下である。
好ましくは、ポリオレフィンはポリエチレンである。
好ましくは、ポリオレフィンはポリプロピレンである。
好ましくは、ポリオレフィンは環状ポリオレフィンである。
好ましくは、環状ポリオレフィンはシクロオレフィンポリマーである。
好ましくは、輸液バッグは50〜100mlバッグである。
好ましくは、容器はアンプルの形態である。
3−メチル−1−フェニル−2−ピラゾリン−5−オン;
3−メチル−1−(2−メチルフェニル)−2−ピラゾリン−5−オン;
3−メチル−1−(3−メチルフェニル)−2−ピラゾリン−5−オン;
3−メチル−1−(4−メチルフェニル)−2−ピラゾリン−5−オン;
3−メチル−1−(3,4−ジメチルフェニル)−2−ピラゾリン−5−オン;
1−(4−エチルフェニル)−3−メチル−2−ピラゾリン−5−オン;
3−メチル−1−(4−プロピルフェニル)−2−ピラゾリン−5−オン;
1−(4−ブチルフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(3−トリフルオロメチルフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(2−メトキシフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(3−メトキシフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−メトキシフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(3,4−ジメトキシフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−エトキシフェニル)−3−メチル−2−ピラゾリン−5−オン;
3−メチル−1−(4−プロポキシフェニル)−2−ピラゾリン−5−オン;
1−(4−ブトキシフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(2−クロロフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(3−クロロフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−クロロフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(3,4−ジクロロフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−フルオロフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(3−クロロ−4−メチルフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(3−メチルメルカプトフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−メチルメルカプトフェニル)−3−メチル−2−ピラゾリン−5−オン;
4−(3−メチル−5−オキソ−2−ピラゾリン−1−イル)安息香酸;
1−(4−エトキシカルボニルフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−ニトロフェニル)−3−メチル−2−ピラゾリン−5−オン;
3−エチル−1−フェニル−2−ピラゾリン−5−オン;
1−フェニル−3−プロピル−2−ピラゾリン−5−オン;
3−フェニル−1−(p−トリル)−2−ピラゾリン−5−オン;
1−(4−メトキシフェニル)−3−フェニル−2−ピラゾリン−5−オン;
1−(4−クロロフェニル)−3−フェニル−2−ピラゾリン−5−オン;
3,4−ジメチル−1−フェニル−2−ピラゾリン−5−オン;
4−イソブチル−3−メチル−1−フェニル−2−ピラゾリン−5−オン;
4−(2−ヒドロキシエチル)−3−メチル−1−フェニル−2−ピラゾリン−5−オン;
3−メチル−4−フェノキシ−1−フェニル−2−ピラゾリン−5−オン;
3−メチル−4−フェニルメルカプト−1−フェニル−2−ピラゾリン−5−オン;
3−(エトキシカルボニルメチル)−1−フェニル−2−ピラゾリン−5−オン;
1−フェニル−2−ピラゾリン−5−オン;
3−メチル−2−ピラゾリン−5−オン;
1,3−ジメチル−2−ピラゾリン−5−オン;
1−エチル−3−メチル−2−ピラゾリン−5−オン;
1−ブチル−3−メチル−2−ピラゾリン−5−オン;
1−(2−ヒドロキエチル)−3−メチル−2−ピラゾリン−5−オン;
1−シクロヘキシル−3−メチル−2−ピラゾリン−5−オン;
1−ベンジル−3−メチル−2−ピラゾリン−5−オン;
1−メチル−3−フェニル−2−ピラゾリン−5−オン;
3−メチル−1−(4−メチルフェニル)−2−ピラゾリン−5−オン;
1−(4−ブチルフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−メトキシフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−ブトキシフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−クロロフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−ヒドロキシフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(3,4−ジヒドロキシフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(2−ヒドロキシフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(3−ヒドロキシフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(3,4−ヒドロキシフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−ヒドロキシフェニル)−3−フェニル−2−ピラゾリン−5−オン;
1−(4−ヒドロキシメチルフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−アミノフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−メチルアミノフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−エチルアミノフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−ブチルアミノフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(4−ジメチルアミノフェニル)−3−メチル−2−ピラゾリン−5−オン;
1−(アセトアミドフェニル)−3−メチル−2−ピラゾリン−5−オン;及び
1−(4−シアノフェニル)−3−メチル−2−ピラゾリン−5−オン
(試験方法)
(1)検体の製造
市販されているラジカット(登録商標)注30mg(三菱ウェルファーマ株式会社製造・販売)の希釈液を、表1に記載の材質の輸液バッグに充填し、エージレス包装後(アルミ袋にエージレスを2個入れ、窒素充填後、封をする)、60℃保存し、1週間目、2週間目及び4週間目の薬液の着色(吸光度400nm)、及びバッグの着色(黄色方向の色度b*(L*a*b*表色系))を評価した。評価項目及び保存条件を表2に示す。
(i)薬液の着色(吸光度400nm)
角形セル(光路長10mm)にて、波長400nmの吸光度を測定する。
分光式色差計(SE−2000、日本電色工業)の試料台(アタッチメント:4径)にバッグ片を置き、その上に白板(三刺激値X0=84.29、Y0=85.54、Z0=101.35)を設置後、反射モードで測定し、黄色方向の色度b*(L*a*b*表色系)を求める。
(1)薬液の着色(吸光度400nm)
薬液の着色の結果を表3に示す。その結果、全ての検体で保存期間を通じて変化はほとんど認められず、無色澄明であった。
バッグの着色の結果を表4に示す。その結果、バッグの着色は(4)PVC>(3)EVA>(2)PE>(1)PE>(7)PE+COP>(6)PE>(5)PP(60℃4W:(4)7.78、(3)5.73、(2)4.17、(1)3.69、(7)3.51、(6)3.45、(5)3.11)の順であった。目視観察の結果、(1)PE、(2)PE、(5)PP、(6)PE及び(7)PE+COPの着色は認められなかったが、(4)PVC及び(3)EVAは明らかに着色が認められた。
本出願は、日本で2005年11月10日に出願された特願2005−326141に基づく優先権を主張する出願であり、特願2005−326141に記載の内容は本明細書にすべて包含されるものである。
Claims (3)
- 3−メチル−1−フェニル−2−ピラゾリン−5−オンを有効成分として含有する水溶液を充填しているプラスチック容器を脱酸素剤と共に収容する気体難透過性の容器であって、上記プラスチック容器がポリエチレン及び環状オレフィンポリマーを重ね合わせて多層にしたものであり、上記プラスチック容器の形態が輸液バックである、気体難透過性の容器。
- 上記プラスチック容器が、60℃で4週間保存前後における黄色方向の色度b*(L*a*b*表色系)の変化Δb*が2以下のプラスチック容器である、請求項1に記載の気体難透過性の容器。
- 60℃で4週間の保存中において、上記水溶液の波長400nmでの吸光度が0.010以下である、請求項1又は2に記載の気体難透過性の容器。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005326141 | 2005-11-10 | ||
JP2005326141 | 2005-11-10 | ||
PCT/JP2006/322447 WO2007055312A1 (ja) | 2005-11-10 | 2006-11-10 | ピラゾロン化合物含有水溶液が充填されたプラスチック容器 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013120415A Division JP2013189469A (ja) | 2005-11-10 | 2013-06-07 | ピラゾロン化合物含有水溶液が充填されたプラスチック容器 |
JP2016104356A Division JP2016155864A (ja) | 2005-11-10 | 2016-05-25 | ピラゾロン化合物含有水溶液が充填されたプラスチック容器 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2007055312A1 JPWO2007055312A1 (ja) | 2009-04-30 |
JP5973118B2 true JP5973118B2 (ja) | 2016-08-23 |
Family
ID=38023307
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007544193A Active JP5973118B2 (ja) | 2005-11-10 | 2006-11-10 | ピラゾロン化合物含有水溶液が充填されたプラスチック容器 |
JP2013120415A Withdrawn JP2013189469A (ja) | 2005-11-10 | 2013-06-07 | ピラゾロン化合物含有水溶液が充填されたプラスチック容器 |
JP2016104356A Withdrawn JP2016155864A (ja) | 2005-11-10 | 2016-05-25 | ピラゾロン化合物含有水溶液が充填されたプラスチック容器 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013120415A Withdrawn JP2013189469A (ja) | 2005-11-10 | 2013-06-07 | ピラゾロン化合物含有水溶液が充填されたプラスチック容器 |
JP2016104356A Withdrawn JP2016155864A (ja) | 2005-11-10 | 2016-05-25 | ピラゾロン化合物含有水溶液が充填されたプラスチック容器 |
Country Status (2)
Country | Link |
---|---|
JP (3) | JP5973118B2 (ja) |
WO (1) | WO2007055312A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5711868B2 (ja) * | 2007-09-28 | 2015-05-07 | テルモ株式会社 | 安定なエダラボン含有水性製剤 |
WO2009066752A1 (ja) | 2007-11-22 | 2009-05-28 | Mitsubishi Tanabe Pharma Corporation | 環状ポリオレフィン層を含むプラスチック容器 |
JP5587597B2 (ja) * | 2008-12-19 | 2014-09-10 | 藤森工業株式会社 | 包装体 |
JP2016022092A (ja) * | 2014-07-18 | 2016-02-08 | ニプロ株式会社 | エダラボン含有プラスチック容器 |
JP7064830B2 (ja) * | 2017-05-12 | 2022-05-11 | 藤森工業株式会社 | 薬液収容プラスチック容器 |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04282162A (ja) * | 1991-03-08 | 1992-10-07 | Green Cross Corp:The | 輸液入りプラスチック容器の製造方法 |
JPH0564653A (ja) * | 1991-06-26 | 1993-03-19 | Terumo Corp | 輸液剤の包装体 |
JPH11114015A (ja) * | 1997-10-09 | 1999-04-27 | Material Eng Tech Lab Inc | 医療用容器 |
JP2000063577A (ja) * | 1998-08-19 | 2000-02-29 | Nissho Corp | 医療用成形品 |
JP2000093490A (ja) * | 1998-09-21 | 2000-04-04 | Jsr Corp | 医療用成形品 |
JP2000504956A (ja) * | 1996-04-10 | 2000-04-25 | フアーマシア・アンド・アツプジヨン・アー・ベー | 非経口流体用改良型容器 |
JP2001157704A (ja) * | 1999-12-02 | 2001-06-12 | Toppan Printing Co Ltd | 輸液用包装材料及びそれを用いた輸液用包装体 |
JP2001162724A (ja) * | 1998-10-22 | 2001-06-19 | Toppan Printing Co Ltd | 低溶出包装材およびそれを用いた包装袋 |
JP2001315276A (ja) * | 2000-05-11 | 2001-11-13 | Mitsui Chemicals Inc | ポリオレフィン積層体 |
WO2002000260A1 (fr) * | 2000-06-29 | 2002-01-03 | Mitsubishi Pharma Corporation | Jp0105585atif contre des maladies du nerf optique et analogue |
JP2002301796A (ja) * | 2001-04-04 | 2002-10-15 | Otsuka Pharmaceut Factory Inc | 多層フィルムおよびそれを用いた容器 |
WO2002092082A1 (en) * | 2001-05-11 | 2002-11-21 | Mitsubishi Pharma Corporation | Stable high-concentration injection containing pyrazolone derivative |
JP2003010287A (ja) * | 2001-03-27 | 2003-01-14 | Nipro Corp | アルブミン溶液収容プラスチック容器 |
JP2003252760A (ja) * | 2002-03-01 | 2003-09-10 | Mitsubishi Pharma Corp | 網膜疾患治療剤および/または予防剤 |
JP2003267871A (ja) * | 2002-03-12 | 2003-09-25 | Natl Inst Of Radiological Sciences | 放射線障害予防剤 |
JP2004300153A (ja) * | 2003-03-20 | 2004-10-28 | Kiyoshi Kurokawa | 蛋白修飾物生成抑制剤 |
WO2004103375A1 (ja) * | 2003-05-22 | 2004-12-02 | Otsuka Pharmaceutical Factory, Inc. | 末梢静脈投与用輸液製剤およびビタミンb1の安定化方法 |
JP2005525952A (ja) * | 2002-05-17 | 2005-09-02 | 株式会社大塚製薬工場 | 多層フィルムおよびそれを用いた薬剤容器 |
JP2005254508A (ja) * | 2004-03-09 | 2005-09-22 | Fujimori Kogyo Co Ltd | 積層フィルムおよび包装袋 |
WO2006118034A1 (ja) * | 2005-04-28 | 2006-11-09 | Otsuka Pharmaceutical Factory, Inc. | 薬液容器収容体およびその製造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07121861B2 (ja) * | 1986-11-25 | 1995-12-25 | 三菱化学株式会社 | 3−メチル−1−フエニル−2−ピラゾロン−5−オンを含有する安定な注射剤 |
JPH09131386A (ja) * | 1995-11-07 | 1997-05-20 | Toyo Ink Mfg Co Ltd | 輸液容器 |
JP4298308B2 (ja) * | 2002-03-28 | 2009-07-15 | 株式会社細川洋行 | 複室輸液容器及びその製造方法 |
JP4335049B2 (ja) * | 2004-03-29 | 2009-09-30 | 中本パックス株式会社 | 輸液バッグ用積層フイルム |
-
2006
- 2006-11-10 JP JP2007544193A patent/JP5973118B2/ja active Active
- 2006-11-10 WO PCT/JP2006/322447 patent/WO2007055312A1/ja active Application Filing
-
2013
- 2013-06-07 JP JP2013120415A patent/JP2013189469A/ja not_active Withdrawn
-
2016
- 2016-05-25 JP JP2016104356A patent/JP2016155864A/ja not_active Withdrawn
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04282162A (ja) * | 1991-03-08 | 1992-10-07 | Green Cross Corp:The | 輸液入りプラスチック容器の製造方法 |
JPH0564653A (ja) * | 1991-06-26 | 1993-03-19 | Terumo Corp | 輸液剤の包装体 |
JP2000504956A (ja) * | 1996-04-10 | 2000-04-25 | フアーマシア・アンド・アツプジヨン・アー・ベー | 非経口流体用改良型容器 |
JPH11114015A (ja) * | 1997-10-09 | 1999-04-27 | Material Eng Tech Lab Inc | 医療用容器 |
JP2000063577A (ja) * | 1998-08-19 | 2000-02-29 | Nissho Corp | 医療用成形品 |
JP2000093490A (ja) * | 1998-09-21 | 2000-04-04 | Jsr Corp | 医療用成形品 |
JP2001162724A (ja) * | 1998-10-22 | 2001-06-19 | Toppan Printing Co Ltd | 低溶出包装材およびそれを用いた包装袋 |
JP2001157704A (ja) * | 1999-12-02 | 2001-06-12 | Toppan Printing Co Ltd | 輸液用包装材料及びそれを用いた輸液用包装体 |
JP2001315276A (ja) * | 2000-05-11 | 2001-11-13 | Mitsui Chemicals Inc | ポリオレフィン積層体 |
WO2002000260A1 (fr) * | 2000-06-29 | 2002-01-03 | Mitsubishi Pharma Corporation | Jp0105585atif contre des maladies du nerf optique et analogue |
JP2003010287A (ja) * | 2001-03-27 | 2003-01-14 | Nipro Corp | アルブミン溶液収容プラスチック容器 |
JP2002301796A (ja) * | 2001-04-04 | 2002-10-15 | Otsuka Pharmaceut Factory Inc | 多層フィルムおよびそれを用いた容器 |
WO2002092082A1 (en) * | 2001-05-11 | 2002-11-21 | Mitsubishi Pharma Corporation | Stable high-concentration injection containing pyrazolone derivative |
JP2003252760A (ja) * | 2002-03-01 | 2003-09-10 | Mitsubishi Pharma Corp | 網膜疾患治療剤および/または予防剤 |
JP2003267871A (ja) * | 2002-03-12 | 2003-09-25 | Natl Inst Of Radiological Sciences | 放射線障害予防剤 |
JP2005525952A (ja) * | 2002-05-17 | 2005-09-02 | 株式会社大塚製薬工場 | 多層フィルムおよびそれを用いた薬剤容器 |
JP2004300153A (ja) * | 2003-03-20 | 2004-10-28 | Kiyoshi Kurokawa | 蛋白修飾物生成抑制剤 |
WO2004103375A1 (ja) * | 2003-05-22 | 2004-12-02 | Otsuka Pharmaceutical Factory, Inc. | 末梢静脈投与用輸液製剤およびビタミンb1の安定化方法 |
JP2005254508A (ja) * | 2004-03-09 | 2005-09-22 | Fujimori Kogyo Co Ltd | 積層フィルムおよび包装袋 |
WO2006118034A1 (ja) * | 2005-04-28 | 2006-11-09 | Otsuka Pharmaceutical Factory, Inc. | 薬液容器収容体およびその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2007055312A1 (ja) | 2007-05-18 |
JP2016155864A (ja) | 2016-09-01 |
JPWO2007055312A1 (ja) | 2009-04-30 |
JP2013189469A (ja) | 2013-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016155864A (ja) | ピラゾロン化合物含有水溶液が充填されたプラスチック容器 | |
JP4666421B2 (ja) | 環状ポリオレフィン層を含むプラスチック容器 | |
CN1929847B (zh) | 含有法舒地尔的制剂及改善其稳定性的方法 | |
TWI476013B (zh) | 具無抗氧化劑注射用溶液形態之含培美曲塞或其鹽的藥物配方之製備方法 | |
KR101846804B1 (ko) | 리파수딜 함유 수성 조성물을 위한 의약 제제 | |
JP5951921B1 (ja) | 組成物 | |
JP5951922B1 (ja) | 水性組成物 | |
EA036212B1 (ru) | Водная композиция, содержащая парацетамол и ибупрофен, и способ ее получения | |
KR20060133059A (ko) | 트라닐라스트를 함유하는 의약 제품 | |
JP2016138085A (ja) | 包装体入り水性医薬製剤 | |
JP2022115886A (ja) | 薬液収容プラスチック容器 | |
JP2016166198A (ja) | 水性組成物 | |
WO2018159702A1 (ja) | 医薬品 | |
EP3753543A1 (en) | Plastic container | |
JP2024500533A (ja) | 可撓性プラスチックバッグ及びミダゾラムの即時使用可能な水溶液を備える医薬品 | |
JP2009143902A (ja) | エダラボンを含有する安定な水溶性製剤 | |
JP2019116505A (ja) | 注射用医薬組成物 | |
JP2008001605A (ja) | ピラゾロン化合物を含有する水溶液剤 | |
JP2005154406A (ja) | オザグレルナトリウム含有水溶液を充填してなる注射用容器 | |
JP6704721B2 (ja) | 水性の組成物 | |
JP6483632B2 (ja) | 新たな水性組成物 | |
JP2018192139A (ja) | 薬液収容プラスチック容器 | |
US20240216272A1 (en) | Pharmaceutical preparation | |
JP2005120016A (ja) | オザグレルナトリウム含有注射剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091015 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120801 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130409 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140131 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140408 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140826 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160525 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160714 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5973118 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |